.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,990,095

« Back to Dashboard

Details for Patent: 5,990,095

Title: Use of hyaluronic acid and forms to prevent arterial restenosis
Abstract:This invention relates to a method of inhibiting the narrowing of the tubular walls of an animal with a form of hyaluronic acid.
Inventor(s): Falk; Rudolf Edgar (Toronto, CA), Ascuali; Samuel Simon (Toronto, CA), Turley; Eva Anne (Winnipeg, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Jul 26, 1995
Application Number:08/448,503
Claims:1. A method of inhibiting the narrowing of the tubular walls of an animal, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof and combination thereof with suitable diluent or carrier to the animal to inhibit narrowing of the tubular walls and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons having a concentration of at least 2% by weight.

2. The method of claim 1, wherein the form of hyaluronic acid is sodium hyaluronate having a molecular weight greater than 150,000 daltons.

3. The method of claim 2, wherein the tubular walls are arteries which have been subjected to balloon angioplasty and the administration of the form of hyaluronic acid takes places before, during or after the balloon angioplasty.

4. The method of claim 2, wherein the amount of the form of hyaluronic acid administered is between 10 mg and 3000 mg.

5. The method of claim 3, wherein the amount of the form of hyaluronic acid administered is between 250 mg and 1500 mg.

6. The method of claim 3, wherein the amount of the form of hyaluronic acid administered is between 500 mg and 1000 mg.

7. The method of claim 4, 5 or 6 further comprising administering a therapeutically effective amount of the form of hyaluronic acid by injection, subcutaneous or intravenous administration.

8. The method of claim 7, wherein the form of hyaluronic acid is administered prior to, during or after the balloon angioplasty.

9. A method of inhibiting arterial restenosis after balloon angioplasty in a human, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof and combination thereof to the human to inhibit arterial restenosis and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons.

10. The method of claim 9, wherein the form of hyaluronic acid is sodium hyaluronate having a molecular weight greater than 150,000 daltons.

11. The method of claim 10, wherein the amount of the form of hyaluronic acid administered is between 10 mg and 3000 mg.

12. The method of claim 10, wherein the amount of the form of hyaluronic acid administered is between 250 mg and 1500 mg.

13. The method of claim 10, wherein the amount of the form of hyaluronic acid administered is between 500 mg and 1000 mg.

14. The method of claim 11, 12 or 13, further comprising administering a therapeutically effective amount of the form of hyaluronic acid by injection, subcutaneous or intravenous administration.

15. The method of claims 1, 2, 3, 5, or 6 wherein the form of hyaluronic acid is sodium hyaluronate administered intravenously.

16. The method of claim 1, 2, 3, 5 or 6 further comprising administering a therapeutically effective amount of a non-steroidal anti-inflammatory drug (NSAID) for targeting underperfused tissue and enhancing the effect of the form of hyaluronic acid administered in the inhibition of the narrowing of tubular walls.

17. The method of claim 16 further comprising administering an effective amount of a drug selected from the group consisting of Vitamin C, an anti-oxidant, a free radical scavenger and a stenosis inhibiting drug for targeting underperfused tissue and enhancing the effect of the form of hyaluronic acid administered in the inhibition of the arterial restenosis.

18. A method inhibiting of arterial restenosis in a patient after balloon angioplasty, the method comprising the administration of a therapeutically effective non-toxic amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof and combination thereof with suitable diluent or carriers wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons having a concentration of 2% by weight.

19. The method of claim 18, wherein the amount of the form of hyaluronic acid administered is between 10mg and 3000 mg.

20. The method of claim 18 or 19 further comprising administering a therapeutically effective amount of an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), restenosis inhibiting drug, Vitamin C, an anti-oxidant and free radical scavenger and combinations thereof for enhancing the arterial restenosis inhibition effect of the administered form of hyaluronic acid.

21. The method of claim 18 or 19 further comprising administering an agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), a restenosis inhibiting drug, Vitamin C, an anti-oxidant, and a free radical scavenger and combinations thereof for enhancing the arterial restenosis inhibition effect of the form of hyaluronic acid administered, the agent being selected in such amount to be effective in enhancing the arterial restenosis inhibition effect of the administered form of hyaluronic acid having a molecular weight of between 150,000 daltons and 225,000 daltons.

22. The method of claim 21 wherein if an NSAID is selected, the amount of the NSAID is an effective dosage amount or a dose excess of the NSAID and the amount of hyaluronic acid and salts thereof exceeds 200 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc